In comparison to the traditional PARP-1 inhibitor, 5F02 inhibited the proliferation of ccRCC cells with greater selectivity and effectiveness, while showing no significant toxicity to normal cells. Here, PARP1 is linked to nonpapillary renal cell carcinoma.